U.S. Markets close in 12 mins

Biopharma M&A: You Ain't Seen Nothing Yet

Barron's has previously discussed how mergers and acquisitions will be a theme for pharma and biotech. With Takeda Pharmaceutical’s (4502.Japan) deal to buy Shire (SHPG), Leerink's Geoffrey Porges takes a look at what other deals could come to fruition. If companies chose to borrow to make acquisitions, that wouldn't be a problem either, he argues, as the group could collectively borrow another $460 billion if the industry returned to its peak leverage ratios, and the biggest companies could easily absorb any acquisitions with little debt worries, especially with synergies.